StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.67−0.02 (-3.29%)

Close on Nov 18, 2026Market cap $40.49MP/E –Yield –

Aldeyra Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aldeyra Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$24.07M. For fiscal 2025 it was -$35.27M. The highest annual figure on record is -$3.68M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$35.27M–
FY2024Dec 31, 2024-$60.12M–
FY2023Dec 31, 2023-$42.79M–
FY2022Dec 31, 2022-$62.68M–
FY2021Dec 31, 2021-$56.22M–
FY2020Dec 31, 2020-$36.42M–
FY2019Dec 31, 2019-$63.07M–
FY2018Dec 31, 2018-$39.70M–
FY2017Dec 31, 2017-$22.49M–
FY2016Dec 31, 2016-$18.70M–
FY2015Dec 31, 2015-$11.99M–
FY2014Dec 31, 2014-$7.27M–
FY2013Dec 31, 2013-$3.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.85M–
Q1 FY2026Mar 31, 2026-$3.55M–
Q4 FY2025Dec 31, 2025-$6.67M–
Q3 FY2025Sep 30, 2025-$8.00M–
Q2 FY2025Jun 30, 2025-$10.17M–
Q1 FY2025Mar 31, 2025-$10.43M–
Q4 FY2024Dec 31, 2024-$16.58M–
Q3 FY2024Sep 30, 2024-$16.14M–
Q2 FY2024Jun 30, 2024-$18.01M–
Q1 FY2024Mar 31, 2024-$9.39M–
Q4 FY2023Dec 31, 2023-$6.10M–
Q3 FY2023Sep 30, 2023-$9.55M–
Q2 FY2023Jun 30, 2023-$10.34M–
Q1 FY2023Mar 31, 2023-$16.80M–
Q4 FY2022Dec 31, 2022-$13.70M–
Q3 FY2022Sep 30, 2022-$14.78M–
Q2 FY2022Jun 30, 2022-$17.71M–
Q1 FY2022Mar 31, 2022-$16.48M–
Q4 FY2021Dec 31, 2021-$15.40M–
Q3 FY2021Sep 30, 2021-$15.44M–
Q2 FY2021Jun 30, 2021-$14.54M–
Q1 FY2021Mar 31, 2021-$10.83M–
Q4 FY2020Dec 31, 2020-$11.29M–
Q3 FY2020Sep 30, 2020-$8.39M–
Q2 FY2020Jun 30, 2020-$7.11M–
Q1 FY2020Mar 31, 2020-$9.64M–
Q4 FY2019Dec 31, 2019-$12.90M–
Q3 FY2019Sep 30, 2019-$19.02M–
Q2 FY2019Jun 30, 2019-$13.73M–
Q1 FY2019Mar 31, 2019-$17.43M–
Q4 FY2018Dec 31, 2018-$11.09M–
Q3 FY2018Sep 30, 2018-$10.95M–
Q4 FY2017Dec 31, 2017-$7.05M–
Q3 FY2017Sep 30, 2017-$5.02M–
Q2 FY2017Jun 30, 2017-$5.33M–
Q1 FY2017Mar 31, 2017-$5.10M–
Q4 FY2016Dec 31, 2016-$4.65M–
Q3 FY2016Sep 30, 2016-$4.78M–
Q2 FY2016Jun 30, 2016-$4.30M–

More Aldeyra Therapeutics figures

See a number that looks wrong?